Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Tal Brosh-Nissimov; Nir Ma'aravi; Daniel Leshin-Carmel; Yonatan Edel; Sharon Ben Barouch; Yafit Segman; Amos Cahan; Erez Barenboim

doi:10.1016/j.jmii.2023.09.004

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Tal Brosh-Nissimov^*, Nir Ma'aravi, Daniel Leshin-Carmel, Yonatan Edel, Sharon Ben Barouch, Yafit Segman, Amos Cahan, Erez Barenboim

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

Original language	English
Pages (from-to)	189-194
Number of pages	6
Journal	Journal of Microbiology, Immunology and Infection
Volume	57
Issue number	1
DOIs	https://doi.org/10.1016/j.jmii.2023.09.004
State	Published - Feb 2024
Externally published	Yes

Keywords

COVID-19
Immunocompromised
Nirmatrelvir
Remdesivir
Tixegavimab/cilgavimab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jmii.2023.09.004

Cite this

Brosh-Nissimov, T., Ma'aravi, N., Leshin-Carmel, D., Edel, Y., Ben Barouch, S., Segman, Y., Cahan, A., & Barenboim, E. (2024). Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab. Journal of Microbiology, Immunology and Infection, 57(1), 189-194. https://doi.org/10.1016/j.jmii.2023.09.004

@article{a10963448b494319b16a27f3229094fa,

title = "Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab",

abstract = "We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.",

keywords = "COVID-19, Immunocompromised, Nirmatrelvir, Remdesivir, Tixegavimab/cilgavimab",

author = "Tal Brosh-Nissimov and Nir Ma'aravi and Daniel Leshin-Carmel and Yonatan Edel and {Ben Barouch}, Sharon and Yafit Segman and Amos Cahan and Erez Barenboim",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = feb,

doi = "10.1016/j.jmii.2023.09.004",

language = "אנגלית",

volume = "57",

pages = "189--194",

journal = "Journal of Microbiology, Immunology and Infection",

issn = "1684-1182",

publisher = "Elsevier Ltd.",

number = "1",

}

Brosh-Nissimov, T, Ma'aravi, N, Leshin-Carmel, D, Edel, Y, Ben Barouch, S, Segman, Y, Cahan, A & Barenboim, E 2024, 'Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab', Journal of Microbiology, Immunology and Infection, vol. 57, no. 1, pp. 189-194. https://doi.org/10.1016/j.jmii.2023.09.004

TY - JOUR

T1 - Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

AU - Brosh-Nissimov, Tal

AU - Ma'aravi, Nir

AU - Leshin-Carmel, Daniel

AU - Edel, Yonatan

AU - Ben Barouch, Sharon

AU - Segman, Yafit

AU - Cahan, Amos

AU - Barenboim, Erez

PY - 2024/2

Y1 - 2024/2

N2 - We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

AB - We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

KW - COVID-19

KW - Immunocompromised

KW - Nirmatrelvir

KW - Remdesivir

KW - Tixegavimab/cilgavimab

UR - http://www.scopus.com/inward/record.url?scp=85173160917&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2023.09.004

DO - 10.1016/j.jmii.2023.09.004

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 37805361

AN - SCOPUS:85173160917

SN - 1684-1182

VL - 57

SP - 189

EP - 194

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

IS - 1

ER -

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this